Aakaar Medical Technologies IPO Receives Lukewarm Response on Day 1; Subscribed 28%

Aakaar Medical Technologies Ltd’s ₹27 crore SME IPO received a tepid response from investors on the first day of bidding, with only 28% of the total issue subscribed as of June 20, 2025.

Subscription Overview

Out of the total 26.83 lakh shares on offer, the IPO garnered bids for 7.48 lakh shares. The highest number of bids came from retail investors and qualified institutional buyers (QIBs), while non-institutional investor interest remained moderate.

Category-Wise Bidding Status:

• Qualified Institutional Buyers (QIBs): 2.38 lakh shares (Foreign Institutional Investors)
• Non-Institutional Investors (NIIs): 2.08 lakh shares
  • Of which, corporates contributed 1.88 lakh shares
• Retail Individual Investors (RIIs): 3.02 lakh shares
  • Cut-off bids: 1.79 lakh
  • Price bids: 1.23 lakh

Price-Wise Bids

• At ₹68 or above: 7.48 lakh shares
• At ₹72 (upper band): 7.44 lakh shares
• Cut-off price: 1.79 lakh shares

The Aakaar Medical Technologies IPO remains open for subscription until June 24, and the company aims to list on the NSE Emerge platform by June 27, 2025.

Issue Details and Business Background

The IPO is entirely a fresh issue comprising 37.5 lakh shares with no offer-for-sale (OFS) component. Proceeds from the offering will be utilized for business expansion. The company, headquartered in Mumbai, manufactures medical and dermatological devices and was founded in 2013.

Disclaimer: This report is for informational purposes only. Investors should consult a SEBI-registered advisor and refer to the red herring prospectus before investing in IPOs.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations